Agency / Source: AnaSpec, Inc.

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

AnaSpec Highlights SensoLyte® 520 Renin Assays for Human, Mouse & Rat Specific - AnaSpec, EGT Group, the provider of the ultra-sensitive SensoLyte® 520 Human Renin Assay Kit also provides renin kits specific for mouse and rat - the
SensoLyte® 520 Mouse Renin Assay Kit and SensoLyte® 520 Rat Renin Assay Kit
AnaSpec Highlights SensoLyte® 520 Renin Assays for Human, Mouse & Rat Specific

 

PRZOOM - /newswire/ - Fremont, CA, United States, 2012/04/09 - AnaSpec, EGT Group, the provider of the ultra-sensitive SensoLyte® 520 Human Renin Assay Kit also provides renin kits specific for mouse and rat - the SensoLyte® 520 Mouse Renin Assay Kit and SensoLyte® 520 Rat Renin Assay Kit.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Using our proprietary 5-FAM/QXL™ 520 fluorescence resonance energy transfer (FRET) peptide, all three assays are ideal for screening of renin inhibitors and for continuous assay of renin activity, especially for high throughput screening (HTS) purposes. In the intact FRET peptide, the fluorescence of 5-FAM is quenched by QXL™ 520. However, upon cleavage into two separate fragments by rat renin, the fluorescence of 5-FAM is recovered, and can be monitored at excitation/emission = 490/520 nm. With a high fluorescence quantum yield and long emission wavelength, the signal of 5-FAM can be detected with less interference from the autofluorescence of cell components and test compounds. The assays are performed in a convenient 96-well microplate format and can be adjusted to 384-well microplate format.

The renin–angiotensin system (RAS) plays a central role in the regulation of blood pressure and electrolyte homoeostasis.1 At the first and rate-limiting step of the RAS cascade, renin, a highly specific aspartyl protease, cleaves angiotensinogen, produced in the liver, to yield angiotensin I, which is further converted into angiotensin II by ACE (Angiotensin Converting Enzyme). Angiotensin II constricts blood vessels leading to increased blood pressure. It also increases the secretion of ADH and aldosterone, and stimulates the hypothalamus to activate the thirst reflex. Since an overactive renin-angiotensin system leads to hypertension, renin is an attractive target for the treatment of this disease. 2-4

References:
1. He, FJ. and GA. MacGregor, J. Renin Angiotensin Aldosterone Syst. 4, 11 (2003).
2. Wood, JM. et al., Hypertension, 7, 797 (1985).
3. Shibasaki, M. et al., Am. J. Hypertens. 4, 932 (1991).
4. Wood, JM.et al., Biochem. Biophys. Res. Comm. 308, 698 (2003).

For more information, please visit anaspec.com/.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: AnaSpec, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


AnaSpec Highlights SensoLyte® 520 Renin Assays for Human, Mouse & Rat Specific

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Tiffany Kao - AnaSpec.com 
510-791-9560
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any AnaSpec, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Press Releases From AnaSpec, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

Ipsen to Present 12 Abstracts At the 11th World Congress for Neurorehabilitation (WCNR) Virtual Congress
Imec Announces elPrep5 - the Newest Version of its Software Platform for DNA Analysis
Ipsen Showcases Commitment to Patient-centric Advances in Oncology with Record Number of Abstracts to be Presented At ESMO 2020 Virtual Congress
Global Phase 3 Clinical Study of Pridopidine in Huntington’s Disease Announced
Ipsen to Present New Insights At ASBMR for Potential Treatment of Ultra-rare Disease Fibrodysplasia Ossificans Progressiva (FOP)
Ipsen to Present Results from MOVE, the First Global Phase III Trial in Fibrodysplasia Ossificans Progressiva (FOP) At ASBMR 2020 Annual Meeting
DSM Ignites New Strategic Initiative to Transform Global Animal Nutrition and Health
Jamjoom Pharmaceuticals Earns Acclaim from Frost & Sullivan for its Dominance in the KSA Pharma Market
DSM and Avril Complete Creation of Joint Venture to Develop Plant-based Protein
Ipsen Joins Clinical Collaboration to Evaluate Cabozantinib (CABOMETYX®) Plus Atezolizumab in Metastatic Non-small Cell Lung Cancer

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
.



PREMIUM Members


Visit  BizJobs.com

Visit  Limelon Advertising, Co.

Visit  Garrison Minerals, LLC







 
  ©2020 PRZOOM - Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today